Description:
The sulfate salt form of LOXO-101, also called Larotrectinib, which is an ATP-competitive inhibitor of tropomyosin receptor kinases. It was approved by FDA for the treatment of metastatic solid tumors.
- Molecular Weight:526.51
- Purity:>95%
Molecular Formula:
C21H24F2N6O6S
Canonical SMILES:
C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F.OS(=O)(=O)O
InChI:
InChI=1S/C21H22F2N6O2.H2O4S/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27;1-5(2,3)4/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31);(H2,1,2,3,4)/t14-,18+;/m0./s1
InChIKey:
PXHANKVTFWSDSG-QLOBERJESA-N
Solubility:
≥ 31 mM in DMSO.
Appearance:
Solid Powder
Storage: Store at -20 °C
Synonyms:
LOXO-101 sulfate; LOXO 101 sulfate; LOXO101 sulfate; Larotrectinib sulfate; (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide sulfate Weitere Informationen finden Sie
hier